Allogene Therapeutics releases Q1 corporate update with focus on allogeneic cell therapy progress

Allogene Therapeutics releases Q1 corporate update with focus on allogeneic cell therapy progress
Allogene Q1 corporate update

Allogene Therapeutics has published its Q1 corporate update, sharing new business milestones and developments for its allogeneic CAR T cell therapy programs.

The company emphasized ongoing momentum in advancing cell therapy initiatives, underscoring commitment to innovation within the sector. Stakeholders are encouraged to review the detailed update for further information about key achievements and clinical advancements in the first quarter.

Earlier this year, Allogene advanced its ALPHA3 trial to evaluate allogeneic CAR T cell therapy in large B-cell lymphoma patients, according to company disclosures. The firm also launched ALLO-329, a therapy targeting autoimmune diseases with its Dagger technology, as reported previously by the company. These initiatives follow ongoing efforts to expand its allogeneic CAR T pipeline.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.